Innovent broadens its Phase 3 NSCLC trial to non‑squamous patients, expanding the potential patient base for its IL‑2/PD‑1 bispecific
Executive summary: Innovent Biologics announced the expansion of its global Phase 3 MarsLight-11 study of IBI363/TAK-928 to include patients with non‑squamous NSCLC. The broadening of eligibility enlarges the trial’s patient pool, potentially strengthening efficacy data and improving prospects for regulatory approval in immunotherapy‑resistant NSCLC.
Who is involved: Innovent Biologics, Takeda (provider of TAK-928), and patients with immunotherapy‑resistant non‑squamous NSCLC.
Likely next: The trial will continue enrolling non‑squamous NSCLC participants and proceed toward efficacy readouts as planned.
Innovent Biologics announced that its global Phase 3 MarsLight-11 study of the alpha‑biased IL‑2/PD‑1 bispecific IBI363/TAK-928 will now enroll patients with non‑squamous NSCLC in addition to the previously enrolled immunotherapy‑resistant cohort. The amendment increases the eligible population and could accelerate data readouts for a drug that targets a mechanism distinct from checkpoint inhibitors alone. The move reflects Innovent’s strategy to deepen its oncology pipeline while leveraging its collaboration with Takeda on TAK-928.
What's next — scenarios
Base Case: Accelerated Enrollment Drives Stronger Data Readouts (60%)
Competitors in the immuno-oncology space must accelerate their own combination trial timelines to counter potential first-mover advantage from Innovent and Takeda.
- Announcement of clinical trial site expansions in US and European registries
- Clinical trial registry updates showing accelerated patient recruitment rates
Upside: Breakthrough Efficacy in Non-Squamous Cohort (25%)
Pharma partners will aggressively scout early-stage alpha-biased IL-2 assets, triggering a surge in licensing valuations and M&A interest in bispecific platforms.
- Presentation of interim response rate data at an upcoming major oncology congress
- Orphan drug or breakthrough therapy designation granted by the US FDA
Downside: Safety Signals Prompt Protocol Adjustments (15%)
Investors will re-price pipeline risk for alpha-biased IL-2 therapies, causing a sector-wide cooling of valuations for similar bispecific constructs.
- Protocol amendment reported to clinicaltrials.gov restricting dosing parameters
- Disclosure of elevated immune-related adverse events leading to patient discontinuations
What to watch
- ClinicalTrials.gov registry updates regarding MarsLight-11 site additions within the next 60 days
- Innovent Biologics upcoming quarterly pipeline disclosures or investor presentations over the next 90 days
- Abstract submission deadlines and acceptance announcements for upcoming oncology conferences in the next 90 days
Timeline
- — Innovent Announces Expansion of Global Phase 3 MarsLight-11 Study of IBI363/TAK-928 (Alpha-biased IL-2/PD-1 Bispecific Fusion Protein) in Immunotherapy-Resistant NSCLC to Include Patients with Non-Squamous NSCLC (PR Newswire)
- — BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC (GlobeNewswire)
Analysis — what this means
Sectors affected
- Non‑small cell lung cancer immunotherapy
Historical parallels
- BlossomHill Therapeutics reported a 45% objective response rate and 88% disease control rate in EGFR C797S‑positive NSCLC (Sept 15 2026)
- Ivonescimab demonstrated positive overall survival in first‑line PD‑L1‑positive NSCLC (Sept 15 2026)
Key entities
Sources
- Innovent Announces Expansion of Global Phase 3 MarsLight-11 Study of IBI363/TAK-928 (Alpha-biased IL-2/PD-1 Bispecific Fusion Protein) in Immunotherapy-Resistant NSCLC to Include Patients with Non-Squamous NSCLC — PR Newswire
- BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC — GlobeNewswire
Related cases
- Akeso's Ivonescimab achieves positive overall survival results against Pembrolizumab in first-line NSCLC treatment
- Sacituzumab govitecan plus pembrolizumab fails to meet primary endpoints in first‑line PD‑L1‑high metastatic NSCLC, dealing a setback to the ADC‑immunotherapy combo approach
- Akeso's Ivonescimab demonstrates superior overall survival compared to Pembrolizumab in PD-L1-positive NSCLC
- Akeso initiates Phase II trial of a novel TROP2/Nectin-4 bispecific ADC combined with Ivonescimab, advancing its oncology pipeline in NSCLC
- Kelun-Biotech’s Phase III trial shows its antibody-drug conjugate plus pembrolizumab beats chemo‑immunotherapy in PD‑L1‑negative NSCLC, potentially reshaping first‑line lung‑cancer treatment